ArticleClinical kidney journal2018
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.
Article in Clinical kidney journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.International urology and nephrology · 2021Pooled it
- Characteristics of pediatric-onset anti-contactin1 antibody-associated autoimmune nodopathies with concomitant membranous nephropathy.BMC pediatrics · 2026Review
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients.Frontiers in immunology · 2026Article
- Comparison of the efficacy of low, moderate and standard doses of rituximab in the treatment of membranous nephropathy.Frontiers in medicine · 2026Article
- Combination of B-cell-guided rituximab and low-dose tacrolimus for primary membranous nephropathy: a retrospective cohort study.Frontiers in medicine · 2026Article
- Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?Journal of nephrology · 2025Review
- B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.Frontiers in immunology · 2025Article
- Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.Frontiers in immunology · 2025Article
- Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review.International journal of nephrology and renovascular disease · 2024Review
- The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab.Clinical kidney journal · 2023Article
- Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.BMC health services research · 2023Article
- Primary membranous nephropathy: an endless story.Journal of nephrology · 2023Review
- EditorialAssignment.BMJ open · 2023Article
- Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis.Archives of medical science : AMS · 2023Review
- Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody.Frontiers in immunology · 2022Article
- Rituximab in patients with membranous nephropathy and kidney insufficiency.Frontiers in pharmacology · 2022Article
- Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.Frontiers in immunology · 2022Review
- Long-term B cell depletion associates with regeneration of kidney function.Immunity, inflammation and disease · 2021Article
- Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.Journal of nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent significant proteinuria has been associated with increased risk of progression to end-stage kidney disease in patients with idiopathic membranous nephropathy (IMN). Rituximab (RTX) therapy has given encouraging results in IMN, but most of the studies have used a higher dose, which is limited by the high cost as well as a potential increased risk of infections. Our study aimed to assess the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN.
methodsA total of 21 patients with treatment-resistant IMN treated with RTX from 2015 to 2016 at our center were included in the study. They received two doses of RTX (500 mg each) infusion 7 days apart. CD19 count was performed after 4 weeks. A single dose of RTX was repeated after 4-6 weeks if CD19 count was not depleted.
resultsThe mean standard deviation age of patients was 33.3 ± 12.3 years and 33.3% were females. Mean proteinuria before RTX therapy was 6.2 ± 2.2 g/day, serum creatinine was 0.9 ± 0.3 mg/dL and estimated glomerular filtration rate (eGFR) was 95.8 ± 26.9 mL/min/1.73 m
conclusionLow-dose RTX therapy is effective and safe in immunosuppression-resistant IMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.